Medical Excellence Capital (MEC)
Medical Excellence Capital (MEC) is an early-stage life sciences venture fund that combines a proprietary global network of leading physician scientists with a team of experienced investment professionals, company builders, and operators. MEC focuses on advancing precision health innovations that address large, unmet medical needs through disruptive technologies in gene therapy, cell therapy, synthetic biology, regenerative medicine, and AI/ML applied to drug discovery.
Portfolio
Aspen Neuroscience is involved in developing autologous neuronal cell replacement therapies for Parkinson’s Disease. They have completed the first and second cohorts in the ASPIRO Phase 1/2a trial. Recently, Aspen Neuroscience announced the first patient dosed in their first-in-human Phase 1/2a clinical trial for Parkinson’s Disease.
#Biotechnology
Immunitas Therapeutics focuses on immuno-oncology drug discovery using a single-cell analysis platform. They are developing a simultaneous NK & T-Cell modulator for hematology and solid tumor therapy. Recently, they appointed Annalisa D’Andrea, Ph.D., as Chief Scientific Officer.
#Biotechnology
Nobias Therapeutics utilizes AI/ML for drug discovery and development, focusing on rare pediatric diseases. They leverage advanced machine learning techniques and proprietary data banks. Recently, Nobias Therapeutics joined the NVIDIA Inception Program for Startups.
#Biotechnology
ProJenX is focused on developing therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. They have announced a partnership to augment ALS clinical trials with a digital twin model. Recently, ProJenX received European authorization for the first study of Prosetin in people living with ALS.
#Biotechnology
Pleno Inc. is developing a platform for early-stage cancer detection using Digital Biology Processing. They recently deployed their RAPTOR Instrument Platform with TotalSeq™ Antibodies from BioLegend.
#Biotechnology
Key People
Managing Partner